Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,797,561
  • Shares Outstanding, K 834,930
  • Annual Sales, $ 3,811 M
  • Annual Income, $ 663,000 K
  • EBIT $ 825 M
  • EBITDA $ 1,025 M
  • 60-Month Beta 0.39
  • Price/Sales 3.09
  • Price/Cash Flow 13.65
  • Price/Book 2.89

Options Overview Details

View History
  • Implied Volatility 51.49% (-2.27%)
  • Historical Volatility 28.08%
  • IV Percentile 43%
  • IV Rank 4.28%
  • IV High 815.48% on 11/28/25
  • IV Low 17.36% on 09/02/25
  • Expected Move (DTE 14) 1.67 (11.78%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 667
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 636
  • Open Int (30-Day) 26,710
  • Expected Range 12.47 to 15.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.16
  • Number of Estimates 1
  • High Estimate 0.16
  • Low Estimate 0.16
  • Prior Year 0.20
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.37 +5.75%
on 11/06/25
14.19 -0.39%
on 12/02/25
+0.67 (+4.97%)
since 11/04/25
3-Month
13.14 +7.61%
on 10/29/25
15.06 -6.08%
on 09/17/25
-0.01 (-0.07%)
since 09/04/25
52-Week
12.26 +15.33%
on 04/09/25
16.17 -12.55%
on 06/12/25
-0.06 (-0.42%)
since 12/04/24

Most Recent Stories

More News
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1 st two cohorts...

RDY : 14.14 (+0.07%)
Is Zoetis Stock Underperforming the Dow?

Zoetis's shares are trailing the broader Dow Jones index, yet analysts still project upside, signaling confidence in the company’s long-term recovery potential.

RDY : 14.14 (+0.07%)
ZTS : 120.41 (-1.76%)
$DOWI : 47,850.94 (-0.07%)
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025

Aurigene Oncology Limited , a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein...

RDY : 14.14 (+0.07%)
Dr. Reddy’s Laboratories to Announce Q2FY26 Results on October 24, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Dr Reddy’s...

RDY : 14.14 (+0.07%)
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS

RDY : 14.14 (+0.07%)
COYA : 6.00 (-2.44%)
Dr. Reddy’s Q1FY26 Financial Results

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned...

RDY : 14.14 (+0.07%)
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

For Immediate ReleaseChicago, IL – April 16, 2025 – Today, Zacks Equity Research Equity are Dr. Reddy’s Laboratories RDY, Sandoz SDZNY and Teva Pharmaceuticals TEVA.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2448907/3-generic-drug-stocks-to-watch-amid-trade-war-jitters-inflation-woesWhile...

SDZNY : 70.7400 (-1.34%)
RDY : 14.14 (+0.07%)
TEVA : 28.41 (+2.08%)
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from...

SDZNY : 70.7400 (-1.34%)
RDY : 14.14 (+0.07%)
TEVA : 28.41 (+2.08%)
2 overlooked stocks that crushed earnings but traded lower

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

WHR : 79.90 (-1.18%)
BAC : 54.16 (+0.13%)
RDY : 14.14 (+0.07%)
NVS : 132.43 (-0.96%)
TEVA : 28.41 (+2.08%)
HSBC : 71.71 (-0.42%)
DB : 36.03 (+0.14%)
PFE : 25.70 (+0.51%)
BMY : 51.95 (+1.94%)
Chart of the Day: What's Cooking at Dr. Reddy's Lab

The Chart of the Day belongs to integrated drug company Dr. Reddy's Laboratories (RDY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy...

RDY : 14.14 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through...

See More

Key Turning Points

3rd Resistance Point 14.27
2nd Resistance Point 14.23
1st Resistance Point 14.19
Last Price 14.14
1st Support Level 14.10
2nd Support Level 14.06
3rd Support Level 14.02

See More

52-Week High 16.17
Fibonacci 61.8% 14.68
Fibonacci 50% 14.22
Last Price 14.14
Fibonacci 38.2% 13.75
52-Week Low 12.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar